Gallego-Rojo F J, Gonzalez-Calvin J L, Muñoz-Torres M, Mundi J L, Fernandez-Perez R, Rodrigo-Moreno D
Department of Gastroenterology, University Hospital of Granada, Spain.
Hepatology. 1998 Sep;28(3):695-9. doi: 10.1002/hep.510280315.
Previous studies suggest that low bone mass is a complication of alcoholic liver disease. Nevertheless, little is known about bone mass and bone metabolism in viral cirrhosis. To evaluate the prevalence and magnitude of hepatic osteopenia in these patients, bone remodeling status, and its relationship with the severity of liver disease and serum levels of insulin-like growth factor I (IGF-I), we studied 32 consecutive patients with viral cirrhosis and no history of alcohol intake. Bone mineral density (BMD) was measured by dual x-ray absorptiometry in the lumbar spine (LS) and femoral neck (FN), and the values were expressed as the z score. Bone metabolism markers and hormone profiles were measured. Patients with viral cirrhosis showed reduced BMD in all sites (LS: -1.27 +/- 1.06, P < .001; FN: -0.48 +/- 0.96; P < .01). Of the 32 patients, 53% met the diagnostic criteria for osteoporosis. In patients, urine deoxypyridinoline (D-Pyr) as a marker of bone resorption and serum bone alkaline phosphatase (b-AP) as a marker of bone formation were significantly higher than in control subjects (P < .001 and P < .01, respectively). Serum IGF-I was lower than in control subjects (P < .001), and significant differences were also found between patients with and without osteoporosis (P < .05). BMD in LS correlated with severity of the disease, with serum levels of IGF-I, and with urine D-Pyr. Our findings show that viral cirrhosis is a major cause of osteoporosis in men, and that low serum IGF-I levels seem to play a role in the bone mass loss in these patients. The biochemical markers of bone remodeling suggest high-turnover osteoporosis in patients with viral cirrhosis.
以往研究表明,低骨量是酒精性肝病的一种并发症。然而,对于病毒性肝硬化患者的骨量和骨代谢情况却知之甚少。为了评估这些患者肝性骨质减少的患病率和严重程度、骨重塑状态及其与肝病严重程度和胰岛素样生长因子I(IGF-I)血清水平的关系,我们对32例无饮酒史的连续性病毒性肝硬化患者进行了研究。采用双能X线吸收法测量腰椎(LS)和股骨颈(FN)的骨密度(BMD),其值以z评分表示。检测骨代谢标志物和激素水平。病毒性肝硬化患者所有部位的骨密度均降低(LS:-1.27±1.06,P<.001;FN:-0.48±0.96;P<.01)。32例患者中,53%符合骨质疏松症的诊断标准。患者作为骨吸收标志物的尿脱氧吡啶啉(D-Pyr)和作为骨形成标志物的血清骨碱性磷酸酶(b-AP)显著高于对照组(分别为P<.001和P<.01)。血清IGF-I低于对照组(P<.001),骨质疏松症患者与非骨质疏松症患者之间也存在显著差异(P<.05)。腰椎的骨密度与疾病严重程度、IGF-I血清水平及尿D-Pyr相关。我们的研究结果表明,病毒性肝硬化是男性骨质疏松症的主要原因,低血清IGF-I水平似乎在这些患者的骨量丢失中起作用。骨重塑的生化标志物提示病毒性肝硬化患者存在高转换型骨质疏松症。